130
Participants
Start Date
March 31, 2016
Primary Completion Date
August 9, 2022
Study Completion Date
April 26, 2024
TAS3681
TAS3681 will be provided as 100 mg tablets to be administered orally in 28-day cycles. The number of cycles is approximately 6, or until discontinuation criteria is met.
MSKCC, New York
Montefiore Medical Center, The Bronx
Hospital Provincial de Castellon, Castellana
Institut Paoli Calmettes, Marseille
University of Maryland Greenebaum Cancer Center, Baltimore
Hospital Universitario Ramon y Cajal, Madrid
Hospital 12 de Octubre, Madrid
Institut Bergonie, Bordeaux
Moffitt Cancer Center, Tampa
Florida Cancer Specialists & Research Institute, Sarasota
Institut régional du Cancer de Montpellier - ICM Val d'Aurelle, Montpellier
Centre eugenie Marquis, Rennes
Hospital Marques de Valdecilla, Santander
UMMC-Cancer Center and Research Institute, Jackson
University of Wisconsin-Carbone Cancer Center, Madison
GU Research Network / Urology Cancer Center, Omaha
Centre Léon BERARD, Lyon
HEGP- Hôpital Européen Georges Pompidou, Paris
Hopital Foch, Suresnes
Gustave Roussy, Villejuif
Univeristy of California Davis Comprehensive Cancer Center, Sacramento
Seattle Cancer Care Alliance, Seattle
Premier Oncology Group, Edison
Hospices Civils de Lyon, Lyon
Sarah Cannon Research Institute UK, London
Centre Antoine Lacassagne, Nice
Hospital Universitari Vall d'Hebron, Barcelona
Institut Catala d Oncologia - L Hospitalet de Llobregat, Barcelona
Hospital Universitari Parc Taulí, Sabadell
The Christie NHS Foundation Trust- The Christie Clinic, Manchester
Royal Marsden Hospital (RMH) NHS Foundation Trust (DDU), Sutton
Royal Marsden Hospital (RMH) NHS Foundation Trust, Sutton
Cambridge University Hospitals NHS Foundation, Cambridge
Taiho Oncology, Inc.
INDUSTRY